What is aml m7?

AML M7 is a subtype of acute myeloid leukemia (AML), which is a type of blood cancer. AML is characterized by the rapid growth of abnormal cells in the bone marrow, which eventually crowd out healthy cells. AML M7 is classified based on the type of cell affected in the bone marrow, and it is named after the FAB (French-American-British) classification system, which is commonly used to classify AML.

AML M7 is also known as acute megakaryoblastic leukemia, because it affects immature cells called megakaryoblasts, which normally give rise to blood platelets. The symptoms of AML M7 are similar to those of other types of AML, including fatigue, weakness, fever, and frequent infections. AML M7 may also cause bleeding and bruising due to low platelet counts.

The diagnosis of AML M7 is made through blood tests, bone marrow biopsy, and other specialized tests. Treatment for AML M7 typically involves chemotherapy, and may also include bone marrow transplant or other supportive care measures. The prognosis for AML M7 depends on several factors, such as the age of the patient, the stage of the disease, and the response to treatment.